Jubilant Pharmova Ltd.

JUBLPHARMA

₹724.5

-0.98% (-7.15)

Market Cap

₹11,495 Cr.

P/E

20.79

About

Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, operates globally in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Novel Drugs busines… Read more

Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, operates globally… Read more

Low

319

52W Range

High

800

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Forensics

9 Yes

Positive for this company

1 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

-1.13%

3yr Average

8.09%

5yr Average

10.45%

Net Profit Margin

Latest

-0.97%

3yr Average

6.5%

5yr Average

8.16%

ROCE

Latest

2.85%

3yr Average

8.73%

5yr Average

10.85%

Debt to Equity

Latest

0.63

3yr Average

0.58

5yr Average

0.71

Market Share

62 %

(as of Mar 18)

Historic

Acetic Anhydride - Domestic Market Share

0.06 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.06 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

0.01 %

(as of Feb 21)

Historic

Neurological - Market Share

0.02 %

(as of Jul 22)

Historic

Pharmaceutical Sector - Market Share

0.03 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

18 %

(as of Mar 18)

Historic

Vitamin B3 - Global Market Share

64 %

(as of Mar 18)

Historic

Vitamin B4 - Domestic Market Share

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up - Contract Research

Location Wise Break-Up - Pharmaceuticals

Location Wise Break-Up

Operating Profit Break-Up

Capex

Asset Break-Up

Operational Metrics

Australia DMF fillings (.)
Source
US DMF Filings (.)
Source
Canada DMF fillings (.)
Source
Japan DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Number of ANDA's Filed in Europe
Source
Number of ANDA's Approved in Europe
Source
Number of ANDA's Filed in Canada
Source
Number of ANDA's Approved by Canada
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Suppliers

Aegis Logistics Ltd.
Balaji Amines Ltd.
Time Technoplast Ltd.
GMM Pfaudler Ltd.
Ganesh Benzoplast Ltd.
TPL Plastech Ltd.
Deep Energy Resources Ltd.

Showing 5 of 7

FAQs on Jubilant Pharmova Ltd. Business

What does Jubilant Pharmova do?

Jubilant Pharmova Limited operates globally in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Novel Drugs with a strong manufacturing presence in Radiopharmaceutical products for regulated markets.

Who are the competitors of Jubilant Pharmova?

Jubilant Pharmova major competitors are Caplin Point Lab, Wockhardt, Marksans Pharma, Strides Pharma Scien, Eris Lifesciences, Procter&Gamble Healt, FDC.
Market Cap of Jubilant Pharmova is ₹11,495 Crs.
While the median market cap of its peers are ₹9,394 Crs.

Is Jubilant Pharmova financially stable compared to its peers?

Jubilant Pharmova seems to be less financially stable compared to its peers.
Altman Z score of Jubilant Pharmova is 2.78 and is ranked 7 out of its 8 competitors.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Mar Jun	Mar Jun Sep Dec		Mar Jun Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec